As filed with the Securities and Exchange Commission on July __, 1996.
Registration No. 33-_____
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
PHARMACEUTICAL FORMULATIONS, INC.
(Exact name of registrant as specified in its charter)
Delaware 22-2367644
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
460 Plainfield Avenue, Edison, New Jersey 08818
(Address of Principal Executive Offices) (Zip Code)
1994 STOCK OPTION PLAN
1994 CHEESMAN STOCK OPTION PLAN
1994 BLACKSHIRE STOCK OPTION PLAN
1994 CALLAHAN STOCK OPTION PLAN
(Full title of the plans)
Frank Marchese, Secretary
Pharmaceutical Formulations, Inc.
460 Plainfield Avenue
Edison, New Jersey 08818
(908) 985-7100
(Name and address, telephone number, including
area code, of agent for service)
Copies of all correspondence to:
David W. Lowden, Esq.
Stroock & Stroock & Lavan
7 Hanover Square
New York, New York 10004
(212) 806-6187
(continued on next page)
<PAGE>
(continuation of cover page)
<TABLE>
<CAPTION>
CALCULATION OF REGISTRATION FEE
Proposed Proposed
maximum maximum
Amount offering aggregate Amount of
Title of securities to be price per offering registration
to be registered registered share (1) price (1) fee
<S> <C> <C> <C> <C>
Common Stock, 1,000,000 $.86 $860,000 $296.56
$.08 par value shares(2)
Common Stock, 75,000 $.86 $ 64,500 $ 22.25
$.08 par value shares(2)
Common Stock, 75,000 $.86 $ 64,500 $ 22.25
$.08 par value shares(2)
Common Stock, 75,000 $.86 $ 64,500 $ 22.25
$.08 par value shares(2)
Total 1,225,000 $1,053,500 $363.31
shares
(1) Estimated solely for purposes of calculating the registration fee pursuant
to Rule 457(h), based on the average of the bid and asked prices on July
16, 1996.
(2) Consists of 1,000,000 shares of Common Stock of the Registrant which are
issuable upon exercise of options which have been granted or will be
granted under the 1994 Stock Option Plan and 75,000 shares of Common Stock
of the Registrant which are issuable upon exercise of options which have
been granted under each of the 1994 Blackshire Stock Option Plan, 1994
Callahan Stock Option Plan and 1994 Cheesman Stock Option Plan.
</TABLE>
<PAGE>
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
This Registration Statement on Form S-8 of Pharmaceutical Formulations,
Inc. a Delaware corporation (the "Registrant"), covers 1,000,000 shares of
common stock, par value $.08 per share, of the Registrant (the "Common Stock")
reserved for issuance under the Registrant's 1994 Stock Option Plan and 75,000
shares of Common Stock reserved for issuance under each of 1994 Blackshire Stock
Option Plan, 1994 Callahan Stock Option Plan and 1994 Cheesman Stock Option
Plan, for a total of 1,225,000 shares of Common Stock.
Item 1. Plan Information
The documents containing the information specified in this Part I will be
sent or given to optionees, as specified by Rule 428(b)(1) promulgated under the
Securities Act of 1933, as amended (the "Securities Act"). Such documents will
not be filed with the Securities and Exchange Commission (the "Commission")
either as part of this Registration Statement or as prospectuses or prospectus
supplements pursuant to Rule 424 under the Securities Act. These documents and
the documents incorporated by reference in the Registration Statement pursuant
to Item 3 of Part II of this Form S-8, taken together, constitute a prospectus
that meets the requirements of Section 10(a) of the Securities Act. See Rule
428(a)(1) under the Securities Act.
Item 2. Registrant Information and Employee Plan Information
(omitted pursuant to procedure described in Item 1 above)
<PAGE>
PART II
INFORMATION REQUIRED IN THE
REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference
The following documents filed with the Commission by the Registrant
(Commission File No. 0-5860) are incorporated herein by reference:
(a) The Registrant's Annual Report on Form 10-K for the fiscal year ended
June 30, 1995.
(b) The Registrant's Quarterly Reports on Form 10-Q for the quarters ended
September 30, 1995, December 31, 1995 and March 31, 1996 and the Registrant's
Current Report on Form 8-K for an event occurring on April 4, 1996; and
(c) The description of the Common Stock which is contained in the
Registrant's Registration Statement on Form 8-A, filed on November 3, 1983,
filed to register such Common Stock pursuant to Section 12(g) of the Securities
Exchange Act of 1934, as amended (the "Exchange Act").
All documents subsequently filed by the Registrant pursuant to Sections
13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this
Registration Statement and prior to the filing of a post-effective amendment
which indicates that all securities offered hereby have been sold or which
deregisters all securities then remaining unsold, shall be deemed to be
incorporated by reference herein and to be a part hereof from the date of filing
of such documents.
Item 4. Description of Securities
(Not applicable)
Item 5. Interests of Named Experts and Counsel
(Not applicable)
Item 6. Indemnification of Directors and Officers
The Registrant's Certificate of Incorporation provides that the Corporation
shall, to the fullest extent permitted by Section 145 of the General Corporation
Law of the State of Delaware, as the same may be amended and supplemented,
indemnify any and all persons whom it shall have power to indemnify under said
section from and against any and all of the expenses, liabilities or other
matters referred to in or covered by said section. Such indemnification shall
not be deemed exclusive of any other rights to which those indemnified may be
entitled under any By-Law, agreement, vote of stockholders or disinterested
directors or otherwise, both as to action in the person's official capacity and
as to action in another capacity while holding such office, and shall continue
as to a person who has ceased to be director, officer, employee or agent and
shall inure to the benefit of the heirs, executors and administrators of such a
person. The Corporation shall provide for the advance payment of all indemnified
expenses. The Registrant's Certificate of Incorporation also contains provisions
limiting or eliminating a director's personal liability to the Registrant or its
stockholders for damages arising from any breach of the director's duty to the
Registrant, except in specified circumstances. Delaware General Corporation Law
Section 145, sets forth the indemnification permitted under Delaware law.
Item 7. Exemption from Registration Claimed
(Not Applicable)
Item 8. Exhibits
Exhibit No. Description
5.1 Opinion of Stroock & Stroock & Lavan with
respect to the shares of Common Stock
registered hereunder.
24.1 Consent of Counsel to be named in the
Registration Statement. Reference is made to
Exhibit 5 to this Registration Statement
which contains a copy of this Consent.
24.2 Consent of BDO Seidman LLP to be named in the
Registration Statement.
Item 9. Undertakings
(a) The Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of the
Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate,
represent a fundamental change in the information set forth in the
registration statement;
(iii) To include any material information with respect to the plan of
distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement;
provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the
registration statement is on Form S-3 or Form S- 8, and the information required
to be included in a post-effective amendment by those paragraphs is contained in
periodic reports filed by the registrant pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934 that are incorporated by reference in the
registration statement.
(2) That, for the purpose of determining any liability under the Securities
Act of 1933, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the termination of the
offering.
(4) If the registrant is a foreign private issuer, to file a post-effective
amendment to the registration statement to include any financial statements
required by Rule 3-19 of Regulation S-X at the start of any delayed offering or
throughout a continuous offering.
(b) The Registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act of 1933, each filing of the Registrant's
annual report pursuant to Section 13(a) or Section 15(d) of the Securities
Exchange Act of 1934 (and, where applicable, each filing of an employee benefit
plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of
1934) that is incorporated by reference in the Registration Statement shall be
deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities
Act of 1933 may be permitted to directors, officers and controlling persons of
the Registrant pursuant to the foregoing provisions, or otherwise, the
Registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Act
and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the Registrant of expenses
incurred or paid by a director, officer or controlling person of the Registrant
in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being
registered, the Registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Act and will be governed by the final adjudication of
such issue.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Registration
Statement to be signed on its behalf by the undersigned thereunto duly
authorized, in the City of New York, State of New York, on the 11th day of July,
1996.
PHARMACEUTICAL FORMULATIONS, INC.
By: /s/ Frank Marchese
---------------------------------
Frank Marchese, Vice President,
Finance
Pursuant to the requirements of the Securities Act, this Registration
Statement has been signed by the following persons in the capacities and on the
dates indicated. Each person whose signature appears below does hereby make,
constitute and appoint Charles LaRosa and Frank Marchese, and each of them, his
true and lawful attorneys and attorney and agents or agent with full power and
authority on his behalf to execute and file with the Securities and Exchange
Commission any amendment or amendments, including post-effective amendments, to
this registration statement, and he does hereby ratify and confirm all his said
attorneys or attorney and agents or agent may do or cause to be done by virtue
hereof.
Signature Title Date
--------- ----- -----
/s/ Charles LaRosa President (Principal July 11, 1996
Charles LaRosa Executive Officer) and
Director
/s/ Frank Marchese Vice President, Finance July 11, 1996
Frank Marchese (Principal Financial
Officer and Principal
Accounting Officer),
Secretary and Treasurer
/s/ Ben Blackshire Director July 11, 1996
Ben Blackshire
/s/ Michael Callahan Director July 11, 1996
Michael Callahan
/s/ Ray Cheesman Director July 11, 1996
Ray Cheesman
/s/ John L. Oram Director July 11, 1996
John L. Oram
/s/ Max A. Tesler Director July 11, 1996
Max A. Tesler
EXHIBIT INDEX
Exhibit
Number Description
5.1 Opinion of Counsel.
24.1 Consent of Counsel, contained in Opinion
of Counsel filed as Exhibit 5.
24.2 Consent of BDO Seidman LLP
EXHIBIT 5.1
212-806-5400
July 16, 1996
Pharmaceutical Formulations, Inc.
460 Plainfield Avenue
Edison, NJ 08818-1904
Gentlemen:
We have acted as counsel to Pharmaceutical Formulations, Inc., a Delaware
corporation (the "Company"), in connection with the preparation and filing with
the Securities and Exchange Commission (the "Commission") under the Securities
Act of 1933, as amended (the "Act"), of a Registration Statement on Form S-8
(the "Registration Statement") relating to the proposed issuance of up to
1,125,000 shares (the "Original Shares") of the Common Stock, $0.08 par value
(the "Common Stock") of the Company, pursuant to the Company's 1994 Stock Option
Plan, 1994 Blackshire Stock Option Plan, 1994 Callahan Stock Option Plan and
1994 Cheesman Stock Option Plan (collectively, the "Plans"), and such additional
shares (the "Additional Shares") as may be issued pursuant to the antidilution
provisions of the Plans. The Original Shares and the Additional Shares are
hereinafter referred to together as the "Shares."
As such counsel, we have examined copies of the Certificate of Incorporation and
By-Laws of the Company, each as amended to the date hereof, the Registration
Statement, the Plans and originals or copies of such other corporate minutes,
records, agreements and other instruments of the Company, certificates of public
officials and other documents, and have made such examinations of law, as we
have deemed necessary to form the basis for the opinion hereinafter expressed.
In our examination of such materials, we have assumed the genuineness of all
signatures, the authenticity of all documents submitted to us as originals and
the conformity to original documents of all copies submitted to us. As to
various questions of fact material to such opinion, we have relied, to the
extent we deemed appropriate, upon representations, statements and certificates
of officers and representatives of the Company and others.
Based upon and subject to the foregoing, we are of the opinion that the Shares,
when issued under the circumstances contemplated in the Registration Statement
and the Plans, will be legally issued, fully paid and non-assessable.
We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement. In giving such consent, we do not admit hereby that we
come within the category of persons whose consent is required under Section 7 of
the Act or the Rules and Regulations of the Commission thereunder.
Very truly yours,
/s/ Stroock & Stroock & Lavan
STROOCK & STROOCK & LAVAN
<PAGE>
EXHIBIT 24.2
CONSENT OF INDEPENDENT
PUBLIC ACCOUNTANTS
We hereby consent to the incorporation by reference in this registration
statement on Form S-8 of our report dated August 30, 1995 relating to the
consolidated financial statements and schedule of Pharmaceutical Formulations,
Inc. appearing in the Company's Annual Report on Form 10-K for the year ended
June 30, 1995.
/s/ BDO Seidman LLP
BDO SEIDMAN LLP
Woodbridge, New Jersey
July 16, 1996
